Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the improvement in airway inflammation in children with asthma non-invasively with exhaled breath NO, a marker of inflammation, after therapy with nebulized budesonide as 0.5mg daily.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AAADRS Clinical Research Center
• Collaborator: AstraZeneca
• Treatments: Budesonide; Nitric Oxide

Criteria

Inclusion Criteria:

• Asthma diagnosis previously for 6 months

• Past asthma medication without change for previous 6 months

• Increased NO levels and ability to perform maneuver

• ICF signed by parents

Exclusion Criteria:

• Systemic steroids in past 60 days,inhaled/nebulized steroids in past 4 weeks

• Hospitalization within 3 months

• Upper or lower airways active infection or cigarette smoke direct exposure

• Use of other asthma medications other than bronchodilators one month prior and during the trial

• Noncompliance